PALISADE BIO, INC. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Palisade Bio reported Q2 2026 results with cash of $125.2M (sufficient through 2H 2027 and early 2028 Phase 2 readouts). The company received FDA IND clearance for Phase 2 ASCENTRA-UC trial (expected to enroll 2H 2026, readout 2H 2027) and plans IND submission for Phase 2 ASCENTRA-CD (1Q 2027 commencement, early 2028 readout). Phase 1 data showed 5/5 UC patients achieved clinical response, 2/5 remission; FSCD cohort achieved 47.5% mean SES-CD score reduction. Q2 net loss was $10.6M vs. $2.8M in prior year; R&D expenses $7.4M vs. $1.7M YoY; G&A $4.8M vs. $1.2M YoY. Board strengthened with additions of Robert Baltera and Jordan Zwick.
Why this rating
For $11.2M company, $125M cash runway and advancing lead asset into Phase 2 with encouraging efficacy are strategically significant. Phase 1 response rates support clinical viability, reducing near-term technical risk materially.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.